Why vital chemotherapy drugs are in short supply in India, Pg2

Key Highlights:

• India is experiencing a critical nationwide shortage of two vital chemotherapy drugs, cisplatin and carboplatin.
• The shortage is primarily due to soaring global platinum raw material costs, disruptions in West Asia shipping routes, and domestic price caps.
• The government, through the National Pharmaceutical Pricing Authority (NPPA), temporarily raised the ceiling rates for these drugs by 50% in June to restart domestic manufacturing.
• This scarcity has led to treatment interruptions and delays for cancer patients across various states, particularly in private hospitals.

Drug Shortage.jpg

Detailed Insights:

• Cisplatin and carboplatin are platinum-based chemotherapy drugs essential for treating a wide range of cancers, including ovarian, lung, and head and neck cancers.
• The global price of platinum, a core raw material, more than doubled, making the production of these price-controlled drugs financially unviable for generic manufacturers.
• Geopolitical conflicts and shipping constraints in West Asia have further restricted the import of raw materials, exacerbating the supply chain issues.
• While some government hospitals had adequate stock or multiple procurement channels, many private facilities and certain state government hospitals faced severe shortages.
• Delays or substitutions with less effective regimens due to the shortage could compromise treatment outcomes, especially in curative-intent cancers.
• Experts suggest long-term strategies such as establishing strategic reserves of essential cancer medicines, diversifying domestic manufacturing, and strengthening API supply chains.

Key Concepts Involved:

• Cisplatin: A first-generation platinum-based chemotherapy drug used to treat various solid tumors and some blood cancers.
• Carboplatin: A second-generation platinum compound, also a chemotherapy drug, widely used for solid tumors.
• Price Caps: Government-imposed maximum prices on essential drugs to ensure affordability and accessibility for the public.
• National Pharmaceutical Pricing Authority (NPPA): A government regulatory body that fixes and revises the prices of controlled bulk drugs and formulations.